目的探究2型糖尿病并发骨质疏松患者血清白脂素(Asprosin)、巨噬细胞炎症蛋白-1β(macrophageinflammato-ry protein-1β,MIP-1β)水平与骨密度及骨代谢指标的相关性。方法选取2022年4月~2023年4月在承德市中心医院就诊的172例2型糖尿...目的探究2型糖尿病并发骨质疏松患者血清白脂素(Asprosin)、巨噬细胞炎症蛋白-1β(macrophageinflammato-ry protein-1β,MIP-1β)水平与骨密度及骨代谢指标的相关性。方法选取2022年4月~2023年4月在承德市中心医院就诊的172例2型糖尿病患者为研究对象,并根据骨密度值结果分为2型糖尿病组(n=103)和2型糖尿病并发骨质疏松组(n=69);采用ELISA法测定血清Asprosin,MIP-1β水平;Pearson法分析血清Asprosin,MIP-1β表达水平与骨密度的相关性;Logistic回归分析2型糖尿病并发骨质疏松的影响因素;受试者工作特征(ROC)曲线分析血清Asprosin,MIP-1β水平对2型糖尿病并发骨质疏松的预测价值。结果与2型糖尿病组比,2型糖尿病并发骨质疏松组患者血清β-CTX(0.48±0.08ng/ml vs 0.42±0.04ng/ml),Asprosin(2.26±0.56ng/ml vs 1.65±0.36ng/ml),MIP-1β(26.01±6.43pg/ml vs 19.46±4.27pg/ml)水平均显著升高,骨密度(0.67±0.13g/cm2 vs 0.84±0.17g/cm2),BGP(8.33±1.23ng/ml vs 9.54±1.42ng/ml),T-P1NP(30.38±3.27ng/ml vs 32.49±3.29ng/ml)水平降低,差异具有统计学意义(t=6.501,8.699,8.032,7.039,5.773,4.133,均P<0.05);Pearson法分析显示,2型糖尿病并发骨质疏松组患者血清Asprosin,MIP-1β水平均与骨密度呈负相关(r=-0.484,-0.498,均P<0.05);Logistic回归分析显示血清Asprosin,MIP-1β水平均为影响2型糖尿病并发骨质疏松发生的独立危险因素(均P<0.05);ROC曲线分析显示,血清Asprosin,MIP-1β水平预测2型糖尿病患者并发骨质疏松的AUC分别为0.768,0.704,联合预测的AUC为0.859,优于二者单独预测(Z=1.812,2.895,均P<0.05)。。结论2型糖尿病患者并发骨质疏松患者血清Asprosin,MIP-1β水平显著升高,二者水平与骨密度密切相关,血清Asprosin,MIP-1β是2型糖尿病发生骨质疏松的独立危险因素,二者联合检测对疾病发展有较高的预测价值。展开更多
Spontaneous bacterial peritonitis (SBP) in patients with cirrhotic liver disease is a serious complication that contributes to the high morbidity and mortality rate seen in this population. Currently, there is a lack ...Spontaneous bacterial peritonitis (SBP) in patients with cirrhotic liver disease is a serious complication that contributes to the high morbidity and mortality rate seen in this population. Currently, there is a lack of consensus amongst the research community on the clinical predictors of SBP as well as the risks and benefits of prophylactic antibiotic therapy in these patients. Pharmacological gastric acid suppression (namely with PPIs and H2RAs) are frequently prescribed for these patients, many times without a clear indication, and may contribute to gut bacterial overflow and SBP development. However, this remains controversial as there are conflicting findings in SBP prevalence between PPI/H2RA-users and non-users. In addition, studies show recent antibiotic use, whether for SBP prophylaxis or for another infectious process, appear to be associated with higher rates of SBP and drug-resistant organisms. Other researchers have also explored the link between zinc, platelet indices (MPV), and macrophage inflammatory protein-1 β (MIP-1β) levels in liver cirrhosis, all of which appear to be promising markers for classifying SBP risk and diagnosis. This literature review was limited by the number and quality of studies available as most are retrospective in nature. Thus, more ongoing, prospective studies and trials are needed to judge the true value of the findings in the studies reviewed in hopes that they can guide appropriate prevention, diagnosis, and management of SBP.展开更多
文摘目的探究2型糖尿病并发骨质疏松患者血清白脂素(Asprosin)、巨噬细胞炎症蛋白-1β(macrophageinflammato-ry protein-1β,MIP-1β)水平与骨密度及骨代谢指标的相关性。方法选取2022年4月~2023年4月在承德市中心医院就诊的172例2型糖尿病患者为研究对象,并根据骨密度值结果分为2型糖尿病组(n=103)和2型糖尿病并发骨质疏松组(n=69);采用ELISA法测定血清Asprosin,MIP-1β水平;Pearson法分析血清Asprosin,MIP-1β表达水平与骨密度的相关性;Logistic回归分析2型糖尿病并发骨质疏松的影响因素;受试者工作特征(ROC)曲线分析血清Asprosin,MIP-1β水平对2型糖尿病并发骨质疏松的预测价值。结果与2型糖尿病组比,2型糖尿病并发骨质疏松组患者血清β-CTX(0.48±0.08ng/ml vs 0.42±0.04ng/ml),Asprosin(2.26±0.56ng/ml vs 1.65±0.36ng/ml),MIP-1β(26.01±6.43pg/ml vs 19.46±4.27pg/ml)水平均显著升高,骨密度(0.67±0.13g/cm2 vs 0.84±0.17g/cm2),BGP(8.33±1.23ng/ml vs 9.54±1.42ng/ml),T-P1NP(30.38±3.27ng/ml vs 32.49±3.29ng/ml)水平降低,差异具有统计学意义(t=6.501,8.699,8.032,7.039,5.773,4.133,均P<0.05);Pearson法分析显示,2型糖尿病并发骨质疏松组患者血清Asprosin,MIP-1β水平均与骨密度呈负相关(r=-0.484,-0.498,均P<0.05);Logistic回归分析显示血清Asprosin,MIP-1β水平均为影响2型糖尿病并发骨质疏松发生的独立危险因素(均P<0.05);ROC曲线分析显示,血清Asprosin,MIP-1β水平预测2型糖尿病患者并发骨质疏松的AUC分别为0.768,0.704,联合预测的AUC为0.859,优于二者单独预测(Z=1.812,2.895,均P<0.05)。。结论2型糖尿病患者并发骨质疏松患者血清Asprosin,MIP-1β水平显著升高,二者水平与骨密度密切相关,血清Asprosin,MIP-1β是2型糖尿病发生骨质疏松的独立危险因素,二者联合检测对疾病发展有较高的预测价值。
文摘Spontaneous bacterial peritonitis (SBP) in patients with cirrhotic liver disease is a serious complication that contributes to the high morbidity and mortality rate seen in this population. Currently, there is a lack of consensus amongst the research community on the clinical predictors of SBP as well as the risks and benefits of prophylactic antibiotic therapy in these patients. Pharmacological gastric acid suppression (namely with PPIs and H2RAs) are frequently prescribed for these patients, many times without a clear indication, and may contribute to gut bacterial overflow and SBP development. However, this remains controversial as there are conflicting findings in SBP prevalence between PPI/H2RA-users and non-users. In addition, studies show recent antibiotic use, whether for SBP prophylaxis or for another infectious process, appear to be associated with higher rates of SBP and drug-resistant organisms. Other researchers have also explored the link between zinc, platelet indices (MPV), and macrophage inflammatory protein-1 β (MIP-1β) levels in liver cirrhosis, all of which appear to be promising markers for classifying SBP risk and diagnosis. This literature review was limited by the number and quality of studies available as most are retrospective in nature. Thus, more ongoing, prospective studies and trials are needed to judge the true value of the findings in the studies reviewed in hopes that they can guide appropriate prevention, diagnosis, and management of SBP.
